Bibliographic Details
| Title: |
Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives |
| Authors: |
Hongliang Jin, Yani Gong, Lin Cheng, Yuanmei Zhu, Zheng Zhang, Yuxian He |
| Source: |
Viruses, Vol 16, Iss 1, p 36 (2023) |
| Publisher Information: |
MDPI AG, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Microbiology |
| Subject Terms: |
SARS-CoV-2, receptor binding motif (RBM), LCB1, multivalent inhibitor, drug resistance, Microbiology, QR1-502 |
| More Details: |
LCB1 is a computationally designed three-helix miniprotein that precisely targets the spike (S) receptor-binding motif (RBM) of SARS-CoV-2, exhibiting remarkable antiviral efficacy; however, emerging SARS-CoV-2 variants could substantially compromise its neutralization effectiveness. In this study, we constructed two multivalent LCB1 fusion proteins termed LCB1T and LCB1T-Fc, and characterized their potency in inhibiting SARS-CoV-2 pseudovirus and authentic virus in vitro. In the inhibition of various SARS-CoV-2 variants, the two LCB1 fusion proteins exhibited markedly improved inhibitory activities compared to LCB1 as anticipated; however, it was observed that relative to the D614G mutation hosting variant, the variants Delta, Lambda, and Omicron BQ.1.1, XBB, XBB.1.5, and EG.5.1 caused various degrees of resistance to the two fusion proteins’ inhibition, with XBB, XBB.1.5, and EG.5.1 variants showing high-level resistance. Moreover, we demonstrated that bat coronavirus RaTG13 and pangolin coronavirus PCoV-GD/PCoV-GX were highly sensitive to two LCB1 fusion proteins, but not LCB1, inhibition. Importantly, our findings revealed a notable decrease in the blocking capacity of the multivalent LCB1 inhibitor on the interaction between the virus’s RBD/S and the cell receptor ACE2 when confronted with the XBB variant compared to WT and the Omicron BA.1 variant. In conclusion, our studies provide valuable insights into the antiviral profiling of multivalent LCB1 inhibitors and offer a promising avenue for the development of novel broad-spectrum antiviral therapeutics. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1999-4915 |
| Relation: |
https://www.mdpi.com/1999-4915/16/1/36; https://doaj.org/toc/1999-4915 |
| DOI: |
10.3390/v16010036 |
| Access URL: |
https://doaj.org/article/3441ed4d6ee34825aa02d1ceb91bb797 |
| Accession Number: |
edsdoj.3441ed4d6ee34825aa02d1ceb91bb797 |
| Database: |
Directory of Open Access Journals |
|
Full text is not displayed to guests. |
Login for full access.
|
